TITLE:
A Case Report: Prolonged Psychosis Secondary to Use of Highly Concentrated Tetra Hydro Cannabinoid (THC) (DABS)
AUTHORS:
Srinivas Dannaram, Madhuri Pulluri, Christina Regan
KEYWORDS:
Schizophrenia, Psychosis, Marijuana, THC
JOURNAL NAME:
Open Journal of Psychiatry,
Vol.12 No.1,
December
31,
2021
ABSTRACT: The Association of Schizophrenia, psychosis, and Marijuana is decades old. Swedish Conscripts cohort study [1] was one of the earlier studies which reported dose-dependent associations between Marijuana use and schizophrenia. This landmark study was substantiated in other countries through research and systematic reviews [2], which further strengthened the dose-dependent association between Marijuana and Psychosis. The dose defined in these studies [1] was based on the frequency of use that is more times used means more risk of developing schizophrenia and or related psychosis. The concept of using highly concentrated marijuana is relatively new, especially in the light of episodes lasting longer than anticipated with treatment resistance. There is not much data on how it will change the course of psychosis and affect the current diagnostic criteria for Substance-induced psychosis, Schizophreniform Psychosis, and schizophrenia. Based on these challenges, we report a case of Dabs or concentrated Tetra Hydro Cannabinoid (THC)-induced prolonged psychosis with tachycardia and treatment resistance on two separate occasions. Both inpatient admissions were triggered using concentrated Tetra Hydro Cannabinoid (THC).